Introduction
Scope
The importance of marketing is increasingly coming to the fore as diabetes-focused companies battle for market superiority. AstraZeneca, Merck & Co. and Novo Nordisk have all expanded their diabetes sales force numbers in recent months, going against the grain of most of the pharmaceutical industry. In an update of a poll run in January looking at physician detailing, this week’s FirstWord Physician Views poll investigates which companies are best at physician marketing in the diabetes space.
Notably, failure to gain approval for Tresiba in the US has led Novo Nordisk to reallocate its marketing spend to aggressively up their promotional effort behind other products such as Victoza. In response, other key players within the diabetes market have increases sales force numbers, entered partnerships or offered more discounts (see Spotlight On: Diabetes marketing battle heats up as hostilities intensify).
With a number of new therapies also entering the market, such as the SGLT-2 inhibitors Invokana (canagliflozin; Johnson & Johnson/Mitsubishi Tanabe) and Forxiga (dapagliflozin; Bristol-Myers Squibb/AstraZeneca), and with Eli Lilly poised to add two viable competitors to the existing GLP-1 market (dulaglutide) and the SGLT-2 space (empagliflozin), competition in the diabetes field is heating up. FirstWord will investigate what prescribers find most important for launch in terms of detailing.
However, amongst the individual classes there appears to be a lack of distinguishing features that clearly differentiate one drug from another and with competition set to increase, a marketing battle will ensue as developers try and out do each other. FirstWord will ask US and 5EU (France, Germany, Italy, Spain and the UK)-based endocrinologists, which are the best detailing diabetes companies and drugs and what factors support this view.
Puchase Reasons
This week's FirstWord Physician Views poll will ask:
Table of Contents
for Physician Views: Which diabetes company does the best marketing job? What is key for companies launching products?
Additional Details
Publisher
FirstWord Pharma
Publisher Information
Reference
61 |
Report Format

Related Reports
Title | Date Published | Price from | More Details |
---|---|---|---|
SAVE 15% today! Physician Views: Can the launch of ViiV Healthcare's dolutegravir disrupt Gilead's dominance in the HIV market? ScopeBased on current timelines, the FDA is poised to approve the HIV therapy dolutegravir later thi... | 01 Aug 2013 by FirstWord Pharma | USD $591 (normally USD $695) |
More Info |
SAVE 15% today! Physician Views: Will generic Copaxone have traction in the MS market given emergence of oral therapies? ScopeA recent ruling by the US Court of Appeals for the Federal Circuit has increased the likelihood... | 01 Aug 2013 by FirstWord Pharma | USD $591 (normally USD $695) |
More Info |
SAVE 15% today! Physician Views: Can GlaxoSmithKline strike early with Anoro? / What role will dosing, inhaler type play in uptake of LAMA/LABA combinations for COPD? ScopeThis year looks set to be one of notable evolution for the US chronic obstructive pulmonary dis... | 01 Aug 2013 by FirstWord Pharma | USD $591 (normally USD $695) |
More Info |
SAVE 15% today! Physician Views: Post ADA view on key diabetes market developments ScopeLast week’s American Diabetes Association (ADA) meeting provided further evidence that the diab... | 01 Jul 2013 by FirstWord Pharma | USD $591 (normally USD $695) |
More Info |
SAVE 15% today! Physician Views: Biosimilar Remicade poised for approval in Europe – are rheumatologists and gastroenterologists ready? ScopeThe recent recommendation to approve a biosimilar version of Merck & Co./Johnson & Johnson's Re... | 01 Jul 2013 by FirstWord Pharma | USD $591 (normally USD $695) |
More Info |
SAVE 15% today! Physician Views: Do EU pulmonologists anticipate rapid uptake for GSK’s Seretide-successor? ScopeAs GlaxoSmithKline's Relvar Ellipta – a once-daily successor to its multi-billion dollar Sereti... | 01 Jul 2013 by FirstWord Pharma | USD $591 (normally USD $695) |
More Info |
SAVE 15% today! Physician Views: Key developments in the European diabetes market - will endocrinologists embrace Tresiba and Forxiga? – both rejected by the FDA ScopeEuropean-based endocrinologists are currently getting to grips with two new products that have ... | 01 Jul 2013 by FirstWord Pharma | USD $591 (normally USD $695) |
More Info |
SAVE 15% today! Physician Views: Recent developments in US diabetes market – impact of safety concerns & emergence of SGLT-2 drug class ScopeWith the diabetes market an important therapeutic area for a host of pharmaceutical manufacture... | 01 Jun 2013 by FirstWord Pharma | USD $591 (normally USD $695) |
More Info |
SAVE 15% today! Physician Views: Life after Gleevec in the chronic myeloid leukaemia (CML) market? ScopeNovartis' Gleevec is widely credited as being one of the most important drug launches of all ti... | 01 Jun 2013 by FirstWord Pharma | USD $591 (normally USD $695) |
More Info |
SAVE 15% today! Surveying Physician Uptake of Mobile Devices and Apps IntroductionThe latest medical application software is increasing physicians’ use of mobile technolo... | 01 Oct 2012 by FirstWord Pharma | USD $591 (normally USD $695) |
More Info |
This report is published by FirstWord Pharma
Download Free Report Summary PDF

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.
Ordering Information
Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.
Accepted Card Types

Buy now using our secure payment system.